Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- 13.9 Bil. in Royalties from Gilenya Help Boost Consolidated Sales for April-December: MTPC
February 5, 2013
- Kyowa Kirin Posts Record Operating Profit for 2012; Sales Up 9% in Pharma Division
February 5, 2013
- Eisai’s Operating Profit Drops 34% in April-December as Aricept Sales Fall
February 4, 2013
- Aricept Fails to Meet Minimum Sales Target in Japan: Eisai
February 4, 2013
- Astellas April-Dec. Earnings: XTANDI Starts Off on Good Note, Could Outstrip Full-Year Target
February 4, 2013
- Kyowa Kirin to Launch 3 In-House Products in Europe and US, Aims for Sales of 358 Billion Yen in 2015: New Midterm Plan
February 4, 2013
- Marketing Ability Could Become Decisive Factor as All DPP-4 Inhibitors Are Likely to Obtain the Same Concurrent-use Indications
February 4, 2013
- Daiichi Sankyo Sees 7.1% Sales Rise in April-December, Cuts Domestic Forecast for Nexium
February 1, 2013
- Chugai Begins Development of Hyperlipidemia Antibody RG7652
February 1, 2013
- Oncology Products Boost Sales, Profits in 2012, but Both Fall Short of Midterm Targets: Chugai
February 1, 2013
- Chugai’s New Midterm Plan Includes No Sales or Profit Targets, Aims for Increased Marketing Productivity
February 1, 2013
- BindRen Approved in Europe for Hyperphosphatemia: MTPC
January 31, 2013
- Chugai Files NDA for Antibody-Drug Conjugate T-DM1 for HER2-Positive Breast Cancer
January 31, 2013
- Higher Dose of Toviaz Further Reduces Urge Urinary Incontinence in Patients with OAB: Pfizer
January 31, 2013
- TS-1 Superior to Gemcitabine in Extending OS of Resected Pancreatic Cancer Patients in PIII Study: Taiho
January 30, 2013
- No New Safety Concerns Found in All-Case PMS of Vectibix: Takeda
January 30, 2013
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
- Number of MR-Qualified MSs Reaches 840 with 376 Newly Passing MR Exam: Medipal Group
January 30, 2013
- Nesina Approved in US: Takeda
January 29, 2013
- Medipal Group Introduces Special Mini Cooler for New Orphan Drug
January 29, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…